RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance?#capitalmarkets?#investorrelations

?? Shareholder Approval Sets Stage for Strategic Transformation at Better Choice Company (NYSE American: BTTR) Better Choice Company (NYSE:BTTR) shareholders overwhelmingly approved the acquisition of SRx Health Solutions, marking a pivotal step toward becoming a broader health and wellness powerhouse. ?? Why This Matters to Investors: ? Acquisition Greenlit: Signals confidence in future growth. ? Rebranding Ahead: Company name will change to SRX Health Solutions, Inc., with a new ticker—SRXH. ? Expanded Vision: Company expands beyond pet wellness, aligning with SRx’s healthcare platform and global opportunities. ?? Read the Full Announcement: https://lnkd.in/eWdYVaBw Veterinary Practice News Veterinary Innovation Hub Biotechnology #HealthcareInnovation #Genomics #PetHealth #Investing #FinancialNews

?? OS Therapies (NYSE American: OSTX) to Meet with Investors at Jones Trading Healthcare and Technology Innovation Conference OS Therapies CEO Paul Romness and CBO Gerald Commissiong will meet with institutional investors to discuss the Company’s progress and future growth plans the Jones Healthcare and Technology Innovation Conference on April 8–9, 2025, in Las Vegas. ?? Why This Matters to Investors: ? Advancing Oncology Pipeline: Lead candidate OST-HER2 completed enrollment for a 41-patient Phase 2b osteosarcoma trial, with data expected in Q4 2024. ? Expanding Innovation: OS Therapies is developing a next-gen tunable ADC (tADC) platform, using proprietary linker tech for enhanced payload delivery. ? Strategic Visibility: The conference provides high-level exposure to capital markets, aligning with OS Therapies' biotech innovation focus. ?? https://lnkd.in/eUCpd56p Biotechnology Antibody Drug Conjugates Journal for ImmunoTherapy of Cancer #RedChip #RedChat #OSTX #BiotechStocks #Immunotherapy #ADC #Investing #CancerResearch #StockMarket

?? PhoenixEV (Nasdaq: PEV) Secures RMB 1 Billion EV Expansion Deal in China! PhoenixEV's EdisonFuture International has partnered with Guorun Venture Capital to launch a RMB 1 billion (~$140M) M&A fund aimed at acquiring and developing EV manufacturing sites in China. This strategic move strengthens PhoenixEV's global EV production footprint, leveraging China’s supply chain advantages to scale cost-efficiently. ?? Why This Matters for Investors: ? Global Expansion: Establishing a foothold in the world’s largest EV market. ? Strategic Growth: Access to low-cost capital and advanced manufacturing. ? Profitability Focus: Enhancing operational efficiencies for sustainable revenue growth. ?? https://lnkd.in/etMX8JHK #PhoenixMotor #PEV #EVStocks #ElectricVehicles #SustainableInvesting

?? Can-Fite BioPharma (NYSE American: CANF) Expands into the $3.8B Veterinary Osteoarthritis Market Can Fite BioPharma (CANFY)'s partner, VETBIOLIX, is accelerating Piclidenoson’s development with an advanced clinical trial targeting canine osteoarthritis. This move follows a successful study and aims to tap into the rapidly growing companion animal arthritis market, projected to hit $6.3B by 2030. ?? Why This Matters to Investors: ? Major Market Potential: Piclidenoson is positioned to capture up to 6% of the market, with projected peak sales of $445M by 2034. ? Revenue Stream for Can-Fite: Can Fite BioPharma (CANFY) receives a 15% royalty, translating to an ~$325M in potential revenue over the next decade. ? Safer Alternative: Unlike NSAIDs, Piclidenoson offers a potentially safer and effective oral treatment for osteoarthritis in pets. ???? With regulatory approval timelines for veterinary drugs often shorter, this could be a fast-track revenue driver for Can Fite BioPharma (CANFY). ?? https://lnkd.in/eQi_eBrp Biotechnology Biotech Network Veterinary Emergency Group Veterinary Practice News #RedChip #RedChat #CanFiteBio #BiotechStocks #CANF #PharmaInvesting #ClinicalTrials

?? PhoenixEV (Nasdaq: PEV) Autonomous Delivery Robot Initiative! PhoenixEV is advancing its autonomous technology initiative with the development of AI-powered package pickup and last-mile delivery robots. This expansion builds on its autonomous food & beverage delivery vehicle program, creating a seamless logistics ecosystem. ?? Why This Matters for Investors: ? Scalable Opportunity: Addressing the booming e-commerce and logistics market with autonomous delivery solutions. ? Strategic Innovation: AI-driven navigation and obstacle detection ensure efficient and secure transport for B2B and B2C applications. ? Market Expansion: Strengthening Phoenix's leadership in sustainable and intelligent transportation technologies. ?? https://lnkd.in/eA-D5iyd #PhoenixMotor #PEV #EVStocks #ElectricVehicles #SustainableInvesting

?? GreenPower Motor Company Inc. (Nasdaq: GP) First Electric School Buses Delivered Under EPA Clean School Bus Program! Round 2 funding of the EPA's Clean School Bus Program has been authorized. This marks a key milestone in deploying 50?GreenPower Motor Company Inc. electric school buses across seven West Virginia school districts as part of an $18.6M award funded by the Infrastructure Investment and Jobs Act. ?? Why This Matters to Investors: ? Government-Backed Growth: Authorized grants support sales of GreenPower's U.S.-manufactured vehicles. ? Scaling EV Adoption: GreenPower's zero-emission school buses support the transition to clean transportation. ? Expansion in Public Fleets: More deliveries are expected in the coming weeks, reinforcing GreenPower's market position in the electric school bus sector. ?? https://lnkd.in/eKHnjZyF auto motor und sport Fundamentals of Electric (EV) and Hybrid Electric Vehicle (HEVs) #RedChip #RedChat #GreenPower #GP #ElectricVehicles #EV #GreenEnergy #Investing #NASDAQ #ZeroEmissions

?? Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) Secures FDA Clearance for Expanded Dosing in Chronic Back Pain Trial! Phase 1/2 clinical trial for CELZ-201-DDT, a regenerative cell therapy targeting chronic lower back pain caused by degenerative disc disease (DDD). ?? Why This Matters to Investors: ? Positive Interim Data: Statistically significant pain reduction and mobility improvements reported. ? Strong Safety Profile: No serious adverse events in the first half of the study. ? Regulatory Milestone: FDA greenlights dose expansion, optimizing treatment outcomes. ? Path to Phase 3: Promising results could accelerate a pivotal Phase 3 trial and potential Biologics License Application (BLA). With chronic back pain impacting millions and opioid alternatives in high demand, CELZ-201-DDT could be a game-changer in pain management. ?? https://lnkd.in/eCFp9jUk #RedChip #RedChat #CreativeMedical #BiotechStocks #RegenerativeMedicine #CELZ #Investing

?? Institutional Confidence in ConnectM (Nasdaq: CNTM) Grows with Latest 7.4% Stake! ARUMILLI LLC acquired 2.1M shares (7.4%) of ConnectM Technology Solutions, raising total institutional ownership to 33%, signaling strong confidence in ConnectM and its growth potential. ?? Why This Matters for Investors: ? Increased institutional backing strengthens market credibility. ? Reflects confidence in ConnectM Technology Solutions's strategic direction and expansion. ? Growing institutional interest could drive long-term value creation. ?? Read the full announcement: https://lnkd.in/dWxRrTU3 #RedChip #RedChat #Electrification #EnergyTech #SustainableInvesting #CleanEnergy #TechStocks #FinancialNews

?? Can-Fite BioPharma (NYSE American: CANF) to Launch Phase II Study for Lowe Syndrome Treatment Can Fite BioPharma (CANFY) is advancing Piclidenoson into a Phase II trial for Lowe Syndrome, a rare genetic disease with no approved treatments. ?? Why Investors Should Watch: ? Regulatory Advantage – Rare disease trials often have expedited pathways. ? Preclinical Success – Piclidenoson reduced urinary protein loss, a key disease marker. ? Strategic Collaboration – Partnered with Fondazione Telethon, a leader in rare disease research. ?? Read More: https://lnkd.in/e-_Ars6F Biotechnology Biotech Network Ospedale Pediatrico Bambino Gesù #RedChip #RedChat #CanFiteBio #BiotechStocks #CANF #PharmaInvesting #ClinicalTrials